RNA vaccine shows promise in advanced melanoma trial

NCT ID NCT02410733

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new RNA cancer vaccine in 119 people with advanced melanoma. The vaccine was designed to train the immune system to attack four proteins found on melanoma cells. The main goal was to check the vaccine's safety and find the best dose, while also looking for signs that it could shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Johann Wolfgang Goethe Universität Frankfurt, Klinik für Dermatologie, Venerologie und Allergologie

    Frankfurt, 60590, Germany

  • Universität Heidelberg, Dermatologie und NCT

    Heidelberg, 69120, Germany

  • Universitätsmedizin Mainz, Hautklinik und Poliklinik

    Mainz, 55131, Germany

  • Universitätsmedizin Mannheim, Klinik für Dermatologie, Venerologie und Allergologie

    Mannheim, 68167, Germany